• Annovis Bio expects offering proceeds and existing cash to fund operations through its pivotal Phase 3 Alzheimer's data readout in March 2027.
• Proceeds from the $21 million public offering will also support continued clinical development of buntanetap for Alzheimer's and Parkinson's diseases.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Annovis Bio Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202611090700PRIMZONEFULLFEED9872995) on November 09, 2026, and is solely responsible for the information contained therein.